Inotek Pharma Files for IPO

By Chris Lange Published Nov 5, 2:00PM EST

Follow 24/7 Wall St. on Google

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

Inotek Pharmaceuticals Corp. has filed an S-1 form with the U.S. Securities and Exchange Commission (SEC) for an initial public offering (IPO). No terms were given for the offering, but the filing is up to $132.25 million. The company will list on the Nasdaq Global Market under the symbol ITEK.

The underwriters for the event were Cowen, Canaccord Genuity, Piper Jaffray and Nomura.

Inotek is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of therapies for glaucoma. Its lead product candidate, trabodenoson, is a first-in-class selective adenosine mimetic designed to lower interocular pressure (IOP) by restoring the eye’s natural pressure control mechanism. Trabodenoson’s unique mechanism of action in the trabecular meshwork should complement the activity of existing glaucoma therapies that exert IOP-lowering effects on different parts of the in-flow and out-flow system of the eye.

The company explained its pipeline as:

Our product pipeline includes trabodenoson monotherapy delivered in an eye drop formulation, as well as a fixed-dose combination, or FDC, of trabodenoson with latanoprost given once-daily, or QD. Statistically significant results for the primary endpoint of our completed Phase 2 clinical trial indicate that trabodenoson monotherapy has IOP-lowering effects in line with the best existing therapies, with a favorable safety and tolerability profile at all doses tested. Our completed Phase 2 trial of trabodenoson co-administered with latanoprost, a prostaglandin analogue, or PGA, demonstrated IOP-lowering in patients who have previously had inadequate responses to treatment with latanoprost. These patients represent PGA poor-responders, as evidenced by persistently elevated IOP at levels that typically require the addition of a second drug to further lower IOP.

Inotek is planning an End-of-Phase 2 meeting with the FDA for trabodenoson monotherapy in the first half of 2015 and expects to initiate a Phase 3 program for it in mid-2015.

According to IMS Health, sales of glaucoma drugs in 2013 were approximately $2.0 billion in the United States and $5.6 billion worldwide. According to the British Journal of Ophthalmology, there were an estimated 2.8 million Americans with glaucoma in 2010.

Inotek plans to use the proceeds from this offering to develop its trabodenoson monotherapy through its clinical phases, as well as repaying its borrowings and terminating its existing notes payable agreements.

ALSO READ: 4 Gold Stocks That Can Survive Despite Tumbling Spot Prices

About the Author Chris Lange →

Chris Lange is a writer for 24/7 Wall St., based in Houston. He has covered financial markets over the past decade with an emphasis on healthcare, tech, and IPOs. During this time, he has published thousands of articles with insightful analysis across these complex fields. Currently, Lange's focus is on military and geopolitical topics.

Lange's work has been quoted or mentioned in Forbes, The New York Times, Business Insider, USA Today, MSN, Yahoo, The Verge, Vice, The Intelligencer, Quartz, Nasdaq, The Motley Fool, Fox Business, International Business Times, The Street, Seeking Alpha, Barron’s, Benzinga, and many other major publications.

A graduate of Southwestern University in Georgetown, Texas, Lange majored in business with a particular focus on investments. He has previous experience in the banking industry and startups.